A 12-Month Phase 3 Study of Pasireotide in Cushing's Disease

Cushing's syndrome

Lacroix, A., Feelders, R. A., Stratakis, C. A., & Nieman, L. K. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61375-1 · Cited by 1,777

Diagnosis and complications of Cushing’s syndrome: a consensus statement

Arnaldi, G., Angeli, A., Atkinson, A. B., Bertagna, X., Cavagnini, F., Chrousos, G. P., Fava, G. A., Findling, J. W., Gaillard, R. C., Grossman, A. B., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030871 · Cited by 1,362

Cushing's syndrome

Newell-Price, J. D. C., BERTAGNA, X. Y., Grossman, A. B., & Nieman, L. K. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68699-6 · Cited by 1,258

Treatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement

Biller, B. M. K., Grossman, A. B., Stewart, P. M., Melmed, S., Bertagna, X., Bertherat, J., Buchfelder, M., Colao, A., Hermus, A. R., Hofland, L. J., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2734 · Cited by 853

Incidence and Late Prognosis of Cushing's Syndrome: A Population-Based Study

Lindholm, J., Juul, S., Jørgensen, J. O. L., Astrup, J., Bjerre, P., Feldt‐Rasmussen, U., Hagen, C., Jørgensen, J. O. L., Kosteljanetz, M., Kristensen, L. Ø., et al. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.1.7093 · Cited by 763

SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile

Bruns, C., Lewis, I., Briner, U., Meno-Tetang, G., & Weckbecker, G. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1460707 · Cited by 692

Morbidity and mortality in Cushing's disease: an epidemiological approach.

Etxabe, J., & Vazquez, J. A. (1994) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1994.tb02486.x · Cited by 622

Incidence and Late Prognosis of Cushing's Syndrome: A Population-Based Study

Lindholm, J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.1.117 · Cited by 505

The Pathophysiological Consequences of Somatostatin Receptor Internalization and Resistance

Hofland, L. J., & Lamberts, S. W. J. (2003) · Endocrine Reviews · doi:10.1210/er.2000-0001 · Cited by 474

The Medical Treatment of Cushing’s Disease: Effectiveness of Chronic Treatment with the Dopamine Agonist Cabergoline in Patients Unsuccessfully Treated by Surgery

Pivonello, R., Martino, M. C. D., Cappabianca, P., Leo, M. D., Faggiano, A., Lombardi, G., Hofland, L. J., Lamberts, S. W. J., & Colao, A. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1533 · Cited by 328

Association Between Mifepristone Dose, Efficacy, and Tolerability in Patients With Cushing Syndrome

Yuen, K. C. J., Williams, G., Kushner, H., & Nguyen, D. (2015) · Endocrine Practice · doi:10.4158/ep15760.or · Cited by 27

Classification and Diagnosis of Diabetes Mellitus

Dennedy, M. C., Rizza, R. A., & Dinneen, S. F. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00038-x · Cited by 28

Currently used and investigational drugs for Cushing´s disease

Ciato, D., Mumbach, A. G., Páez-Pereda, M., & Stalla, G. K. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1266338 · Cited by 27

Pituitary-Directed Therapies for Cushing’s Disease

Langlois, F., Chu, J. M., & Fleseriu, M. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00164 · Cited by 26

High Expression of Somatostatin Receptors 2A, 3, and 5 in Corticotroph Pituitary Adenoma

Behling, F., Honegger, J. B., Skardelly, M., Gepfner‐Tuma, I., Tabatabai, G., Tatagiba, M. S., & Schittenhelm, J. (2018) · International Journal of Endocrinology · doi:10.1155/2018/1763735 · Cited by 26

A Review on the Metabolism of 25 Peptide Drugs

Chia, C. S. B. (2021) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-021-10177-0 · Cited by 26

Drug resistance in pituitary tumours: from cell membrane to intracellular signalling

Peverelli, E., Treppiedi, D., Mangili, F., Catalano, R., Spada, A., & Mantovani, G. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00514-0 · Cited by 26

Cell specific interaction of pasireotide: review of preclinical studies in somatotroph and corticotroph pituitary cells

Gatto, F., Arvigo, M., Amarù, J., Campana, C., Cocchiara, F., Graziani, G., Bruzzone, E., Giusti, M., Boschetti, M., & Ferone, D. (2018) · Pituitary · doi:10.1007/s11102-018-0926-y · Cited by 26

Eurasian clinical guidelines for the diagnosis and treatment of secondary (symptomatic) forms of arterial hypertension (2022)

Chazova, I. E., Михайловна, Ч. Н., Blinova, N. V., Belaya, Z. E., Danilov, N. M., Elfimova, E. M., Litvin, A. Y., Rozhinskaya, L. Y., Sviridenko, N. Y., Швецов, М. Ю., et al. (2023) · Eurasian heart journal · doi:10.38109/2225-1685-2023-1-6-65 · Cited by 30

Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing’s disease

Feelders, R., Fleseriu, M., Kadıoğlu, P., Bex, M., González-Devia, D., Boguszewski, C., Yavuz, D. G., Patino, H., Pedroncelli, A., Maamari, R., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1165681 · Cited by 14

Targeting the somatostatin receptor in pituitary and neuroendocrine tumors

Veenstra, M. J., de Herder, W. D., Feelders, R., & Hofland, L. (2013) · Expert opinion on therapeutic targets · doi:10.1517/14728222.2013.830711 · Cited by 19

Disease-specific quality of life evaluation and its determinants in Cushing’s syndrome: what have we learnt?

Badia, X. C., Valassi, E., Roset, M., & Webb, S. M. (2013) · Pituitary · doi:10.1007/s11102-013-0484-2 · Cited by 25

Successful Medical Treatment of Adult Nesidioblastosis With Pasireotide over 3 Years: A Case Report

Schwetz, V., Horvath, K., Kump, P., Lackner, C., Perren, A., Forrer, F., Pieber, T. R., Treiber, G., Sourij, H., & Mader, J. K. (2016) · Medicine · doi:10.1097/md.0000000000003272 · Cited by 25

Clinicopathological analysis of 250�cases of pituitary adenoma under the new WHO classification

Liu, J., He, Y., Zhang, X., Xiao-ling, Y. A. N., & Huang, Y. (2020) · Oncology Letters · doi:10.3892/ol.2020.11263 · Cited by 25

Advances in the Medical Treatment of Cushing Disease

Tritos, N. A., & Biller, B. M. K. (2020) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2020.05.003 · Cited by 25

Update on Current Evidence for the Diagnosis and Management of Nonfunctioning Pituitary Neuroendocrine Tumors

Whyte, E., Nezu, M., Chik, C. L., & Tateno, T. (2023) · Endocrinology and Metabolism · doi:10.3803/enm.2023.1838 · Cited by 24

Computer Vision Technology in the Differential Diagnosis of Cushing’s Syndrome

Popp, K. H., Kosilek, R. P., FROHNER, R. N., Stalla, G. K., Athanasoulia-Kaspar, A. P., Berr, C., Zopp, S., Reincke, M., Witt, M., Würtz, R. P., et al. (2019) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0887-4233 · Cited by 24

USP8 inhibitor RA-9 reduces ACTH release and cell growth in tumor corticotrophs

Treppiedi, D., Muro, G. D., Marra, G., Barbieri, A. M., Mangili, F., Catalano, R., Serban, A. L., Ferrante, E., Locatelli, M., Lania, A. G., et al. (2021) · Endocrine Related Cancer · doi:10.1530/erc-21-0093 · Cited by 24

Adrenal Mild Hypercortisolism

Goddard, G. M., Ravikumar, A., & Levine, A. C. (2015) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2015.02.009 · Cited by 24

Inhibitory effects of SOM230 on adrenocorticotropic hormone production and corticotroph tumor cell proliferation in vitro and in vivo

Murasawa, S., Kageyama, K., Sugiyama, A., Ishigame, N., Niioka, K., Suda, T., & Daimon, M. (2014) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2014.07.001 · Cited by 24

Clinical use of pasireotide for Cushing's disease in adults

Boscaro, M., Ceccato, F., & Scaroni, C. M. (2015) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s37314 · Cited by 24

Management Strategies for Aggressive Cushing's Syndrome: From Macroadenomas to Ectopics

Pozza, C., Graziadio, C., Giannetta, E., Lenzi, A., & Isidori, A. M. (2012) · Journal of Oncology · doi:10.1155/2012/685213 · Cited by 24

Medical Therapy for Cushing’s Syndrome in the Twenty-first Century

Tritos, N. A., & Biller, B. M. K. (2018) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2018.01.006 · Cited by 24

Utilization of macrocyclic peptides to target protein-protein interactions in cancer

Yang, J., Zhu, Q., Wu, Y., Xiao-juan, Q., Liu, H., Jiang, B., Ge, D., & Song, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.992171 · Cited by 22

Clinical Guidelines for the Diagnosis and Treatment of Cushing's Disease in Korea

Hur, K. Y., Kim, J. H., Kim, B.-J., Kim, M., Lee, E. J., & Kim, S.-W. (2015) · Endocrinology and Metabolism · doi:10.3803/enm.2015.30.1.7 · Cited by 23

Syndromes de Cushing : physiopathologie, étiologie et principes thérapeutiques

Chabre, O. (2014) · La Presse Médicale · doi:10.1016/j.lpm.2014.02.001 · Cited by 21

Osilodrostat improves blood pressure and glycemic control in patients with Cushing’s disease: a pooled analysis of LINC 3 and LINC 4 studies

Fleseriu, M., Pivonello, R., Newell-Price, J. D. C., Gadelha, M. R., Biller, B. M. K., Auchus, R. J., Feelders, R. A., Shimatsu, A., Witek, P., Bex, M., et al. (2025) · Pituitary · doi:10.1007/s11102-024-01471-3 · Cited by 23

The Potential of Peptide-Based Inhibitors in Disrupting Protein–Protein Interactions for Targeted Cancer Therapy

Afonso, A. L., Cavaleiro, C. T., Castanho, M. A. R. B., Neves, V., & Cavaco, M. C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073117 · Cited by 26

Salivary cortisol is a useful tool to assess the early response to pasireotide in patients with Cushing’s disease

Trementino, L., Cardinaletti, M., Concettoni, C., Marcelli, G., Polenta, B., Spinello, M., Boscaro, M., & Arnaldi, G. (2014) · Pituitary · doi:10.1007/s11102-014-0557-x · Cited by 22

MANAGEMENT OF ENDOCRINE DISEASE: Can we cure Cushing’s disease? A personal view

BERTAGNA, X. Y. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0062 · Cited by 22

Pasireotide treatment reduces cardiometabolic risk in Cushing’s disease patients: an Italian, multicenter study

Albani, A., Ferraù, F., Ciresi, A., Pivonello, R., Scaroni, C. M., Iacuaniello, D., Zilio, M., Guarnotta, V., Alibrandi, A., Messina, E., et al. (2018) · Endocrine · doi:10.1007/s12020-018-1524-5 · Cited by 22

The treatment with pasireotide in Cushing’s disease: effect of long-term treatment on clinical picture and metabolic profile and management of adverse events in the experience of a single center

Simeoli, C., Ferrigno, R., Martino, M. C. D., Iacuaniello, D., Papa, F., Angellotti, D., Pivonello, C., Patalano, R., Negri, M., Colao, A. A. L., et al. (2019) · Journal of Endocrinological Investigation · doi:10.1007/s40618-019-01077-8 · Cited by 22

Development of potent selective competitive-antagonists of the melanocortin type 2 receptor

Bouw, E., Huisman, M., Neggers, S. J. C. M. M., Themmen, A. P. N., van der Lely, A. J., & Delhanty, P. J. D. (2014) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2014.07.003 · Cited by 22

Effects of subcutaneous pasireotide on cardiac repolarization in healthy volunteers: A single‐center, phase I, randomized, four‐way crossover study

Breitschaft, A., Hu, K., Darstein, C., Ligueros‐Saylan, M., Jordaan, P., Song, D., Hudson, M., & Shah, R. R. (2013) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.213 · Cited by 21

Ectopic ACTH-secreting pituitary adenomas within the sphenoid sinus

Johnston, P. C., Kennedy, L., Weil, R. J., & Hamrahian, A. H. (2014) · Endocrine · doi:10.1007/s12020-014-0313-z · Cited by 21

Medical Management of Functioning Pituitary Adenoma: An Update

Oki, Y. (2014) · Neurologia medico-chirurgica · doi:10.2176/nmc.ra.2014-0239 · Cited by 21

Regulation of Endogenous (Male) Rodent GLP-1 Secretion and Human Islet Insulin Secretion by Antagonism of Somatostatin Receptor 5

Farb, T. B., Adeva, M., Beauchamp, T. J., Cabrera, O., Coates, D. A., Meredith, T. D., Droz, B. A., Efanov, A. M., FICORILLI, J. V., Gackenheimer, S. L., et al. (2017) · Endocrinology · doi:10.1210/en.2017-00639 · Cited by 21

Current and Emerging Medical Therapies in Pituitary Tumors

Sahakian, N., Castinetti, F., Brue, T. C., & Cuny, T. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11040955 · Cited by 20

P720R USP8 Mutation Is Associated with a Better Responsiveness to Pasireotide in ACTH-Secreting PitNETs

Treppiedi, D., Marra, G., Muro, G. D., Esposito, E., Barbieri, A. M., Catalano, R., Mangili, F., Bravi, F., Locatelli, M., Lania, A. G., et al. (2022) · Cancers · doi:10.3390/cancers14102455 · Cited by 20

Genetically engineered human pituitary corticotroph tumor organoids exhibit divergent responses to glucocorticoid receptor modulators

Mallick, S., Chakrabarti, J. L., Eschbacher, J. M., Moraitis, A. G., Greenstein, A. E., Churko, J. M., Pond, K. W., Livolsi, A., Thorne, C. A., Little, A. S., et al. (2023) · Translational research · doi:10.1016/j.trsl.2023.01.002 · Cited by 20

The Adrenal Cortex

Stewart, P. M., & Newell-Price, J. D. C. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00015-0 · Cited by 24

Cushing's disease

Ferrière, A., & Tabarin, A. (2021) · La Presse Médicale · doi:10.1016/j.lpm.2021.104091 · Cited by 20

Medical therapies in pituitary adenomas: Current rationale for the use and future perspectives

Cuny, T., Barlier, A., Feelders, R. A., Weryha, G., Hofland, L. J., Ferone, D., & Gatto, F. (2014) · Annales d Endocrinologie · doi:10.1016/j.ando.2014.10.002 · Cited by 19

Glucose metabolism disorders in patients with adrenal gland disorders: pathophysiology and management

Ioakim, K. J., Sydney, G. I., & Paschou, S. Α. (2019) · HORMONES · doi:10.1007/s42000-019-00147-z · Cited by 19

Impact of cortisol on blood pressure and hypertension-mediated organ damage in hypertensive patients

Haddad, C., Courand, P., Berge, C., Harbaoui, B., & Lantelme, P. (2021) · Journal of Hypertension · doi:10.1097/hjh.0000000000002801 · Cited by 19

Effect of liraglutide on dietary lipid‐induced insulin resistance in humans

Koška, J., Lopez, L. K., D’Souza, K. M., Osredkar, T., Deer, J., Kurtz, J., Salbe, A. D., Harman, S. M., & Reaven, P. D. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13037 · Cited by 21

To Market, To Market—2012

Bronson, J. J., Black, A., Dhar, T. G. M., Ellsworth, B. A., & Merritt, J. R. (2013) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-417150-3.00028-4 · Cited by 18

Multiple once-daily subcutaneous doses of pasireotide were well tolerated in healthy male volunteers: a randomized, double-blind, placebo-controlled, cross-over, Phase I study

Beglinger, C., Hu, K., Wang, Y., Bouillaud, E., Darstein, C., Wang, Y.-F., & Mohideen, P. (2012) · Endocrine · doi:10.1007/s12020-012-9668-1 · Cited by 19

Specific biology of neuroendocrine tumors: Peptide receptors as molecular targets

Körner, M. (2016) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2016.01.001 · Cited by 18

Effects of pasireotide treatment on coagulative profile: a prospective study in patients with Cushing’s disease

Barbot, M., Guarnotta, V., Zilio, M., Ceccato, F., Ciresi, A., Daniele, A., Pizzolanti, G., Campello, E., Frigo, A. C., Giordano, C. S. D. S., et al. (2018) · Endocrine · doi:10.1007/s12020-018-1669-2 · Cited by 18

Metformin suppresses growth and adrenocorticotrophic hormone secretion in mouse pituitary corticotroph tumor AtT20 cells

Jin, K., Ruan, L., Pu, J., Zhong, A., Wang, F., Tan, S., Huang, H., Mu, J., & Yang, G. (2018) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2018.07.007 · Cited by 18

The clinical significance of somatostatin in pancreatic diseases.

Śliwińska-Mossoń, M., Vesely, M., & Milnerowicz, H. (2014) · Annales d'Endocrinologie · doi:10.1016/j.ando.2014.06.004 · Cited by 18

Preincubation of Pituitary Tumor Cells With the Epidrugs Zebularine and Trichostatin A Are Permissive for Retinoic Acid-Augmented Expression of the BMP-4 and D2R Genes

Yacqub‐Usman, K., Duong, C. V., Clayton, R. N., & Farrell, W. E. (2013) · Endocrinology · doi:10.1210/en.2013-1061 · Cited by 18

The management of Cushing's disease - from investigation to treatment.

Juszczak, A., & Grossman, A. B. (2013) · PubMed · Cited by 17

Effective Long-Term Treatment of Cushing’s Disease with Pasireotide: A Case Report

Lü, L., Duan, L., Jin, Z., Lu, Z., & Gu, F. (2013) · Endocrine Practice · doi:10.4158/ep12296.cr · Cited by 17

Pasireotide in Acromegaly: An Overview of Current Mechanistic and Clinical Data

Samson, S. (2015) · Neuroendocrinology · doi:10.1159/000381460 · Cited by 15

Subcutaneously Administered Self-Cleaving Hydrogel–Octreotide Conjugates Provide Very Long-Acting Octreotide

Schneider, E. L., Henise, J., Reid, R. R., Ashley, G. W., & Santi, D. V. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00188 · Cited by 17

Levoketoconazole: a novel treatment for endogenous Cushing's syndrome

Fleseriu, M., Auchus, R. J., Pivonello, R., Salvatori, R., Zacharieva, S., & Biller, B. M. K. (2021) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2021.1945440 · Cited by 18

Role of SST, CORT and ghrelin and its receptors at the endocrine pancreas

Chanclón, B., Martínez‐Fuentes, A. J., & Gracia‐Navarro, F. (2012) · Frontiers in Endocrinology · doi:10.3389/fendo.2012.00114 · Cited by 17

Common Histologically Benign Tumors of the Brain

Strowd, R. E., III, & Blakeley, J. O. (2017) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000541 · Cited by 17

Chemotherapy-Induced Regression of an Adrenocorticotropin-Secreting Pituitary Carcinoma Accompanied by Secondary Adrenal Insufficiency

Cornell, R. F., Kelly, D. F., Bordo, G., Carroll, T. B., Duong, H. T., Kim, J. J., Takasumi, Y., Thomas, J. P., Wong, Y. L., & Findling, J. W. (2013) · Case Reports in Endocrinology · doi:10.1155/2013/675298 · Cited by 17

Safety and Efficacy of Subcutaneous Pasireotide in Patients With Cushing's Disease: Results From an Open-Label, Multicenter, Single-Arm, Multinational, Expanded-Access Study

Fleseriu, M., Iweha, C., Salgado, L. R., Mazzuco, T. L., Campigotto, F., Maamari, R., & Limumpornpetch, P. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00436 · Cited by 16

Progress in the Stereoselective Synthesis Methods of Pyrrolidine-Containing Drugs and Their Precursors

Smolobochkin, А. V., Gazizov, A. S., Appazov, N. O., Sinyashin, O. G., & Burilov, A. R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252011158 · Cited by 19

Osilodrostat (LCI699), a potent 11β-hydroxylase inhibitor, administered in combination with the multireceptor-targeted somatostatin analog pasireotide: A 13-week study in rats

Li, L., Vashisht, K., Boisclair, J., Li, W., Lin, T., SCHMID, H. A., Kluwe, W. M., Schoenfeld, H. A., & Hoffmann, P. (2015) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2015.05.004 · Cited by 16

Medical Management of Cushing Disease

Tritos, N. A., & Biller, B. M. K. (2019) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2019.05.007 · Cited by 16

Long-term safety and efficacy of subcutaneous pasireotide in patients with Cushing’s disease: interim results from a long-term real-world evidence study

Manetti, L., Deutschbein, T., Schopohl, J., Yuen, K. C. J., Roughton, M., Kriemler‐Krahn, U., Tauchmanovà, L., Maamari, R., & Giordano, C. S. D. S. (2019) · Pituitary · doi:10.1007/s11102-019-00984-6 · Cited by 16

Characterization of persistent and recurrent Cushing’s disease

Sundaram, N. K., Carluccio, A. L., & Geer, E. B. (2013) · Pituitary · doi:10.1007/s11102-013-0511-3 · Cited by 16

Update and Practical Recommendations for the Use of Medical Treatment of Cushing Syndrome

Araujo-Castro, M., Lamas, C., Nowak, E., Newell-Price, J. D. C., Reincke, M., & Castinetti, F. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf042 · Cited by 19

Neurology of the pituitary

Samarasinghe, S., Emanuele, M. A., & Mazhari, A. (2013) · Handbook of clinical neurology · doi:10.1016/b978-0-7020-4087-0.00047-4 · Cited by 15

Clinical management of critically ill patients with Cushing’s disease due to ACTH-secreting pituitary macroadenomas: effectiveness of presurgical treatment with pasireotide

Cannavò, S., Messina, E., Albani, A., Ferraù, F., Barresi, V., Priola, S. M., Esposito, F., & Angileri, F. F. (2015) · Endocrine · doi:10.1007/s12020-015-0601-2 · Cited by 15

Current approaches to the pharmacological management of Cushing's disease

Molitch, M. E. (2014) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2014.09.021 · Cited by 15

Systemic therapy of Cushing’s syndrome

Eckstein, N., Haas, B., Hass, M. D. S., & Pfeifer, V. (2014) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-014-0122-8 · Cited by 15

Molecular Mechanisms of Glucocorticoid Resistance in Corticotropinomas: New Developments and Drug Targets

Ciato, D., & Albani, A. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00021 · Cited by 15

Regulation of the EGFR Pathway by HSP90 Is Involved in the Pathogenesis of Cushing’s Disease

Shen, Y., Ji, C., Jian, X., Zhou, J., Zhang, Q., Qiao, N., Zhang, Y., Shou, X., Zhou, X., & Ma, Z. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.601984 · Cited by 15

Pharmacokinetics and safety of subcutaneous pasireotide and intramuscular pasireotide long-acting release in Chinese male healthy volunteers: a phase I, single-center, open-label, randomized study.

Chen, X., Shen, G.-X., Jiang, J., Liu, H.-Z., Hu, K., Darstein, C., Lasher, J., & Hu, P. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.06.006 · Cited by 14

Repeat stereotactic radiosurgery for Cushing’s disease: outcomes of an international, multicenter study

Mehta, G. U., Ding, D., Gupta, A., Kano, H., Sisterson, N. D., Martínez-Moreno, N., Kršek, M., Yang, H.-C., Lee, C.-C., Liščák, R., et al. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-2817-5 · Cited by 12

Pasireotide in Cushing's Disease

Targher, G. (2012) · New England Journal of Medicine · doi:10.1056/nejmc1204078 · Cited by 15

Emerging drugs for Cushing’s disease

Guelho, D., & Grossman, A. B. (2015) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2015.1047762 · Cited by 14

Effect of AP102, a subtype 2 and 5 specific somatostatin analog, on glucose metabolism in rats

Tarasco, E., Seebeck, P., Pfundstein, S., Daly, A., Eugster, P. J., Harris, A., Grouzmann, E., Lutz, T., & Boyle, C. (2017) · Endocrine · doi:10.1007/s12020-017-1386-2 · Cited by 12

Library Construction, Selection and Modification Strategies to Generate Therapeutic Peptide-Based Modulators of Protein–Protein Interactions

Baxter, D., Ullman, C. G., & Mason, J. M. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.14.134 · Cited by 14

Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushing's syndrome and acromegaly

Baroni, M. G., Giorgino, F., PEZZINO, V., Scaroni, C. M., & Avogaro, A. (2016) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2016.02.001 · Cited by 14

Fine‐tuning somatostatin receptor signalling by agonist‐selective phosphorylation and dephosphorylation: IUPHAR Review 5

Schulz, S., Lehmann, A., Kliewer, A., & Nagel, F. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12551 · Cited by 14

Current strategies for the treatment of severe Cushing’s syndrome

Alexandraki, K., & Grossman, A. B. (2015) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2016.1123615 · Cited by 14

From Genes to Therapy: Pituitary Adenomas in the Era of Precision Medicine

Toader, C., Dobrin, N., Tătaru, C.-I., Covache-Busuioc, R.-A., Bratu, B.-G., Glavan, L.-A., Costin, H. P., Corlatescu, A.-D., Dumitrascu, D.-I., & Ciurea, A. V. (2023) · Biomedicines · doi:10.3390/biomedicines12010023 · Cited by 13

Medical combination therapies in Cushing’s disease

Vilar, L., Naves, L. A., Machado, M. C., & Bronstein, M. D. (2015) · Pituitary · doi:10.1007/s11102-015-0641-x · Cited by 13

The role of an acute pasireotide suppression test in predicting response to treatment in patients with Cushing’s disease: findings from a pilot study

Trementino, L., Zilio, M., Marcelli, G., Michetti, G., Barbot, M., Ceccato, F., Boscaro, M., Scaroni, C. M., & Arnaldi, G. (2014) · Endocrine · doi:10.1007/s12020-014-0499-0 · Cited by 13

Somatostatin analogs regulate tumor corticotrophs growth by reducing ERK1/2 activity

Treppiedi, D., Giardino, E., Catalano, R., Mangili, F., Vercesi, P., Sala, E., Locatelli, M., Arosio, M., Spada, A., Mantovani, G., et al. (2019) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2018.12.022 · Cited by 13

Is pasireotide-induced diabetes mellitus predictable? A pilot study on the effect of a single dose of pasireotide on glucose homeostasis

Barbot, M., Regazzo, D., Mondin, A., Zilio, M., Lizzul, L., Zaninotto, M., Plebani, M., Arnaldi, G., Ceccato, F., & Scaroni, C. M. (2020) · Pituitary · doi:10.1007/s11102-020-01055-x · Cited by 14

Pituitary acting drugs: cabergoline and pasireotide

Gadelha, M. R., Wildemberg, L. E., & Shimon, I. (2022) · Pituitary · doi:10.1007/s11102-022-01238-8 · Cited by 13

Medical treatment of Cushing’s disease with concurrent diabetes mellitus

Mehlich, A., Bolanowski, M., Mehlich, D., & Witek, P. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1174119 · Cited by 13

Recent advances in the medical treatment of Cushing’s disease

Fleseriu, M. (2014) · F1000Prime Reports · doi:10.12703/p6-18 · Cited by 13

Nelson syndrome: definition and management.

Barber, T. M., Adams, E., & Wass, J. A. (2014) · Handbook of Clinical Neurology · doi:10.1016/b978-0-444-59602-4.00022-8 · Cited by 16

Immunohistochemical expression of somatostatin receptors SSTR2A and SSTR5 in 299 pituitary adenomas

Fuchs, T. L., Sioson, L., Sheen, A., Clarkson, A., & Gill, A. J. (2018) · Pathology · doi:10.1016/j.pathol.2017.10.024 · Cited by 13

New and emerging drug therapies for Cushing’s disease

Störmann, S., & Schopohl, J. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1504021 · Cited by 14

Filamin A is required for somatostatin receptor type 5 expression and pasireotide-mediated signaling in pituitary corticotroph tumor cells

Treppiedi, D., Muro, G. D., Mangili, F., Catalano, R., Giardino, E., Barbieri, A. M., Locatelli, M., Arosio, M., Spada, A., Peverelli, E., et al. (2021) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2021.111159 · Cited by 13

Role of “old” pharmacological agents in the treatment of Cushing’s syndrome

Ambrogio, A. G., & Cavagnini, F. (2016) · Journal of Endocrinological Investigation · doi:10.1007/s40618-016-0462-4 · Cited by 12

A Critical Evaluation of sst3 and sst5 Immunohistochemistry in Human Pituitary Adenomas

Körner, M., Waser, B., Christ, E., Beck, J., & Reubi, J. C. (2017) · Neuroendocrinology · doi:10.1159/000472563 · Cited by 12

Pancreas and Adverse Drug Reactions: A Literature Review

Sosnowski, K., Nehring, P., & Przybyłkowski, A. M. (2022) · Drug Safety · doi:10.1007/s40264-022-01204-0 · Cited by 13

Paradoxical and atypical responses to pasireotide in aggressive ACTH-secreting pituitary tumors

Greenman, Y., & Stern, N. (2016) · Pituitary · doi:10.1007/s11102-016-0755-9 · Cited by 12

New Treatments for the Carcinoid Syndrome.

Loughrey, P., Zhang, D., & Heaney, A. (2018) · Endocrinology and metabolism clinics of North America (Print) · doi:10.1016/j.ecl.2018.04.014 · Cited by 9

Pasireotide: A Review of Its Use in Cushing’s Disease

McKeage, K. (2013) · Drugs · doi:10.1007/s40265-013-0052-0 · Cited by 32

Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial.

Boscaro, M., Ludlam, W., Atkinson, B., Glusman, J., Petersenn, S., Reincke, M., Snyder, P. J., Tabarin, A., Biller, B., Findling, J., et al. (2009) · Journal of Clinical Endocrinology and Metabolism · doi:10.1210/jc.2008-1008 · Cited by 276

Medical Treatment of Cushing’s Disease: Somatostatin Analogues and Pasireotide

Pedroncelli, A. M. (2010) · Neuroendocrinology · doi:10.1159/000314352 · Cited by 39

Pasireotide for the treatment of Cushing's disease

Colao, A., Simeoli, C., de Leo, M., Cozzolino, A., & Pivonello, R. (2013) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2013.807731 · Cited by 2

A Single-Center 10-Year Experience with Pasireotide in Cushing’s Disease: Patients’ Characteristics and Outcome

Trementino, L., Michetti, G., Angeletti, A., Marcelli, G., Concettoni, C., Cardinaletti, C., Polenta, B., Boscaro, M., & Arnaldi, G. (2016) · Hormone and Metabolic Research · doi:10.1055/s-0042-101347 · Cited by 28